8-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of LY2940094 Administered Once Daily in Patients With Major Depressive Disorder (MDD)
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2017
At a glance
- Drugs BTRX 246040 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 29 May 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 24 Jan 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
- 11 Dec 2012 New trial record